Monitor for actual sales under this ATM program, as the $6.36 million represents a ceiling rather than a guaranteed amount. The capital will support PH-762 development but introduces dilution risk. Check future 10-Q filings for disclosure of shares sold and net proceeds received.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 9 $1.25entry
- T+1 · 7mo ago −3.20%α −3.14% · $1.21
- T+5 · 7mo ago +1.60%α −1.59% · $1.27
- T+20 · 6mo ago −8.00%α −15.57% · $1.15
- T+60 · 4mo ago −20.80%α −31.58% · $0.9900
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 million in common stock. This capital raise follows a recent shelf registration and is intended to fund development of PH-762 and general working capital. The offering introduces potential near-term dilution.
Key Financial Metrics
Key Facts
- Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 million in common stock
- The offering is being conducted pursuant to a shelf registration statement declared effective on July 1, 2024
- Proceeds will be used to advance PH-762 into a Phase 2b/3 trial and for general working capital
- H.C. Wainwright will receive a 3.0% commission on gross proceeds from sales
- The company has no obligation to sell any shares and may suspend or terminate the offering at any time
Financial Impact
Up to $6.36 million in potential proceeds, with 3.0% commission paid to the placement agent
Risk Factors
- Dilution to existing shareholders if the full $6.36 million is raised
- Potential downward pressure on stock price from incremental share issuance
- No assurance that any shares will be sold under the agreement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-011761 |
| Exhibit: ex_942764.htm | 0001437749-26-011761 |
| Document: phio20260402_8k.htm | 0001437749-26-011761 |
| Document: 0001437749-26-011761-index-headers.html | 0001437749-26-011761 |
| Document: 0001437749-26-011761-index.html | 0001437749-26-011761 |
| Document: 0001437749-26-011761.txt | 0001437749-26-011761 |
Track record
7 reports on PHIO
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.8013 to $0.7710 Now $0.7520 +6.15% ▲ +3.78% +6.38% vs SPY
- Oct 13, 20264w ago 8-K Neutral 3/10 Entry $0.9345 to $0.8921 Now $0.7520 −19.53% ▼ −4.54% −3.39% vs SPY
- Sep 14, 20269w ago 8-K Bullish 5/10 Entry $1.03 to $1.01 Now $0.7520 −26.99% ▼ −1.94% −2.05% vs SPY
- Aug 14, 202613w ago DEFA14A Neutral 3/10 Entry $1.06 to $1.17 Now $0.7520 −29.06% ▲ +10.38% +11.57% vs SPY
- Apr 8, 202631w ago 8-K Neutral 5/10 Viewing Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
- Apr 8, 202631w ago 424B5 Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
- Mar 5, 202636w ago 8-K Mixed 6/10 Entry $1.16 to $1.17 Now $0.7520 −35.17% ▲ +0.86% +2.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers